Abbott Laboratories (ABT)
$
132.85
+0.83 (0.62%)
Key metrics
Financial statements
Free cash flow per share
3.8101
Market cap
228.4 Billion
Price to sales ratio
5.3949
Debt to equity
0.1414
Current ratio
1.7805
Income quality
0.6651
Average inventory
6.4 Billion
ROE
0.2450
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $10,834,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $16,419,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $11,697,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $7.64 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $132.85 appealing to a broad range of investors. With a large market capitalization of $231,137,744,000.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 7,202,133.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Abbott Laboratories stock to fluctuate between $99.71 (low) and $141.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-05-30, Abbott Laboratories's market cap is $231,137,744,000, based on 1,739,840,000 outstanding shares.
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Abbott Laboratories pays dividends. The current dividend yield is 1.81%, with a payout of $0.59 per share.
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
Revenue: $41,950,000,000 | EPS: $7.74 | Growth: 134.55%.
Visit https://www.abbott.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
zacks.com
Abbott (ABT) closed the most recent trading day at $132.85, moving +0.63% from the previous trading session.
seekingalpha.com
Abbott remains a Buy at $131 for its steady cash flow, strong fundamentals, and long-term healthcare growth, despite short-term revenue concerns. Wall Street underestimates ABT's operational discipline, product pipeline, and ability to manage legal and macro risks, supporting its premium valuation. Risks include legal issues, reimbursement cuts, product recalls, and FX volatility, but the company's track record and cash reserves provide confidence.
247wallst.com
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
fool.com
Broader equities have been volatile this year, but that's par for the course. The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest.
247wallst.com
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
zacks.com
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
zacks.com
Per REFLECT studies, ABT's Libre technology is the first CGM linked to fewer hospitalizations for heart complications in people with diabetes.
zacks.com
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
youtube.com
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.
See all news